Company and Stock Identity

How BenevolentAI Connects to the Public Market

Company structure
Private company after a 2025 delisting
Market access
No current public listing. Shares were delisted from Euronext Amsterdam on March 13, 2025.
Research focus
Separate current platform and partnership work from the former public-company pipeline, and date every source because the structure changed materially in 2025.

BenevolentAI completed a merger and returned to private ownership in March 2025. Old pages and documents may still show the former BAI ticker.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... BenevolentAI ... Company source

BenevolentAI completes its merger and leaves Euronext Amsterdam

The company said its merger resolutions passed, the prior entity ceased to exist, and its shares would be delisted the next day.

Why it matters: The merger means BenevolentAI should no longer be presented as a current public stock. Older pages can keep circulating after a company changes structure, which makes the date of every ownership and market claim important. This update is the line between the former listing and the company that exists now.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: AI drug discovery, computational biology, knowledge graphs, product, scientific partnerships, and business development.

Qualification signal: Life-sciences roles often need advanced scientific or computational training. Commercial and product roles still benefit from drug-discovery evidence rather than a general AI certificate.

Check current roles at BenevolentAI. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Pharmaceutical R&D, biotechnology leadership, translational science, business development, and investors
Primary use case
Identify targets, design molecules, prioritize experiments, and connect biomedical data to research decisions
Typical deployment
Ranges from software and data partnerships to platform collaborations and internally owned drug pipelines

Evidence questions

  • Which results are prospective, reproduced, and tied to a clinical or experimental endpoint?
  • How many programs are AI-originated, AI-assisted, partnered, or internally owned?
  • What has advanced beyond target identification and preclinical reporting?

Regulatory and workflow questions

  • Which entity owns development, validation, and regulatory responsibility for each program?
  • How are model-generated hypotheses reviewed before experimental or clinical use?
  • What claims are about research productivity versus a regulated product?

Data and contract questions

  • Who owns generated molecules, targets, models, and derived data?
  • Which proprietary datasets create defensibility and which are licensed?
  • Can a partner reproduce outputs and export project data after the collaboration?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources